🔗 Share this article

While the US undertakes historic adjustments to its vaccine guidelines, one figure has emerged unexpectedly: Tracy Beth Høeg, a US-based sports physician and public health researcher who first made her name by casting doubt on COVID-19 vaccinations throughout the pandemic and has concentrated on potential deaths after COVID-19 immunization in her recent position at the FDA.

Proposed Changes to Pediatric Vaccine Program

Agency leaders planned to reveal major changes to the pediatric vaccine schedule in December, synchronizing the US with the Danish national calendar, sources say – a major change that would place the US out of step with a large portion of the world with little proof for improved outcomes. The announcement has been pushed back until the new year.

In place of the top vaccines chief, Tracy Beth Høeg is set to speak at the gathering. She was just designated interim head of the FDA’s drug evaluation center, the fifth person to head the office this calendar year.

A New Direction at the FDA

Høeg's temporary position could signify a strengthened alliance between the drug and biologics divisions as Dr. Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it signals a increased emphasis upon rolling back previously authorized vaccines at the FDA.

The new acting director has repeatedly called for halting specific pediatric shot schedules in the US so as to align more similar to Denmark's approach, a society with universal health coverage and a citizenry about the size of Wisconsin’s.

So far comments, she has persisted in emphasizing on vaccination policy – usually the purview of Prasad, chief of the FDA’s vaccine center – rather than pharmaceutical oversight.

Questions Over Qualifications

Dr. Høeg has no obvious experience in drug development, oversight or leadership, which has been standard for past leaders of the CBER. She has been employed at the FDA as a key advisor to the commissioner and the vaccine center since spring.

“She doesn’t seem to have the necessary background” for overseeing the CDER, stated Jonathan Howard. “She lacks experience running a randomized controlled trial. She has no expertise in leading a large organization. She has no expertise in drug approvals.”

Past directors of the center would “understand laws and regulations and the underlying principles of drug development”, said a former acting FDA commissioner. “Frankly, she lacks the sort of resume that previous people who headed the center have had.”

The drug center has an enormous portfolio at the FDA, the former commissioner pointed out.

“The public just pays attention on the new drug program, but the off-patent medication office authorizes thousands of generic drugs. There’s a biologic copycat branch, OTC medication office and other areas, and each of these have to be managed,” Dr. Woodcock noted. “The area you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

Additionally, a major leadership aspect to the job, which supervises more than 5,000 staff members. “It’s a huge administrative position, if you perform it correctly,” Woodcock concluded.

Response and Contentious Policies

When asked about questions about Dr. Høeg's credentials and whether this assignment signifies increased cooperation among agency officials on immunizations, a spokesperson responded that the “questions are based on inaccurate presumptions”.

“Her experience matches the functions of her position,” the representative explained, citing the months Dr. Høeg spent guiding the FDA commissioner on “medication safety and regulatory science, including computational safety modeling and vaccine surveillance”.

As the temporary head, Dr. Høeg takes over the commissioner’s new expedited review system, a disputed expedited medication authorization process that allegedly worried her predecessors. “By what process are these medications being picked for this voucher program? Who makes the decisions?” Dr. Howard said. “There’s a lot of confidentiality going on at the FDA right now.”

Overall, he said, “the FDA appears to be shifting towards laxer oversight of most medications, with the exception of vaccines.”

Established Track Record on Vaccines

With vaccines, Dr. Høeg has a more documented, if problematic, track record, some experts observe. She authored a study using unverified public submissions to determine the rate of myocarditis following COVID-19 immunization. She counseled the Florida chief medical officer Joseph Ladapo, who reportedly have modified findings to indicate Covid vaccines are pose a greater threat than they are.

Included in her “policy goals” for the current federal leadership featured changing regulations for recently developed shots and discontinuing “optional” vaccines, she said after the election on a online show. At the FDA, Dr. Høeg has allegedly floated the idea of barring adolescent males from getting Covid vaccines.

“She’s an all-around dogmatist who starts off with her preconceived notions and reverse-engineers to fit the evidence in a very deceptive, dishonest way,” Dr. Howard said.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg joined other skeptics, {like|